Great Point Light

Great Point Partners Expands Transatlantic Value Creation Through London Office Opening

Retrieved on: 
Monday, May 1, 2023

Great Point Partners (“GPP”), a Greenwich-based private investment firm, has opened an office in London, expanding the firm’s ability to help growing health care companies reach transatlantic scale.

Key Points: 
  • Great Point Partners (“GPP”), a Greenwich-based private investment firm, has opened an office in London, expanding the firm’s ability to help growing health care companies reach transatlantic scale.
  • The expansion is part of Great Point Partners’ strategy to integrate both its North American and European networks to support existing and prospective portfolio companies with global growth.
  • “Our London office will enable us to strengthen our partnerships with entrepreneurs to build global health care businesses,” said Jeffrey Jay, M.D., Founder and Managing Partner of GPP.
  • GPP will continue to manage its European investing activities through an integrated team based out of both Greenwich and London.

China Wantian Holdings Completes the Acquisition of Domestic Fresh Food Supply Chain Service Provider

Retrieved on: 
Friday, November 25, 2022

It marks the Group's expansion of its fresh food ingredient business into the Guangdong-Hong Kong-Macao Greater Bay Area (the "Greater Bay Area") market.

Key Points: 
  • It marks the Group's expansion of its fresh food ingredient business into the Guangdong-Hong Kong-Macao Greater Bay Area (the "Greater Bay Area") market.
  • It sources live cattle from Inner Mongolia and distributes them to slaughterhouses in the Greater Bay Area.
  • Looking ahead, China Wantian Holdings aims to enhance the diversity of its development strategies by expanding its businesses.
  • The Group is principally engaged in food supply, catering chain and environmental protection and technology.

China Wantian Holdings Proposes to Acquire Domestic Fresh Food Supply Chain Service Provider

Retrieved on: 
Monday, November 7, 2022

It marks the Group's expansion of its fresh food ingredient business into the Guangdong-Hong Kong-Macao Greater Bay Area (the "Greater Bay Area") market.

Key Points: 
  • It marks the Group's expansion of its fresh food ingredient business into the Guangdong-Hong Kong-Macao Greater Bay Area (the "Greater Bay Area") market.
  • Upon the acquisition completion, the Target Group will become wholly-owned subsidiaries of China Wantian Holdings and their financial results will be consolidated into China Wantian Holdings' consolidated financial statements.
  • The Target Group which the Group proposes to acquire is principally engaged in the trading of live cattle, fruits, vegetables, seafoods and food ingredients in the PRC.
  • In May 2022, China Wantian Holdings established its Greater Bay Area headquarters in Shenzhen, marking its official debut in the Greater Bay Area market.

iXCells Biotechnologies Secures Strategic Growth Investment from Great Point Partners

Retrieved on: 
Thursday, September 29, 2022

iXCells Biotechnologies (iXCells or the Company), a high growth provider of cell-based products and discovery services to the academic, biotech and pharmaceutical communities worldwide, with special focus on primary and induced pluripotent stem cell (iPSC) derived cellular models, today announced receiving a growth investment from Connecticut-based Great Point Partners (GPP), a private investment firm focusing on the healthcare industry.

Key Points: 
  • iXCells Biotechnologies (iXCells or the Company), a high growth provider of cell-based products and discovery services to the academic, biotech and pharmaceutical communities worldwide, with special focus on primary and induced pluripotent stem cell (iPSC) derived cellular models, today announced receiving a growth investment from Connecticut-based Great Point Partners (GPP), a private investment firm focusing on the healthcare industry.
  • Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with 30 professionals, investing in the United States, Canada, and Western Europe.
  • Great Point manages $1.5B of capital in its private funds and public life sciences equity strategy (BioMedical Value Fund).
  • Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 200 growing health care companies.

Great Point Partners Completes Investment in Ephicacy Consulting Group to Fund Accelerated Growth

Retrieved on: 
Friday, July 22, 2022

GREENWICH, Conn. and ISELIN, N.J., July 22, 2022 /PRNewswire-PRWeb/ -- Today Great Point Partners ("GPP"), a Greenwich-based private investment firm focused on the health care industry, announced a growth investment and partnership with Ephicacy Consulting Group, Inc., ("Ephicacy"), a leading biometrics Contract Research Organization ("CRO") with operations in the United States, Canada, and India. The Company was founded in 2005 by Ganesh Gopal, its Chief Executive Officer. Ephicacy provides statistical programming, data management, and real-world evidence ("RWE") analytics services to pharmaceutical and biotechnology companies around the world.

Key Points: 
  • GREENWICH, Conn. and ISELIN, N.J., July 22, 2022 /PRNewswire-PRWeb/ --Today Great Point Partners ("GPP"), a Greenwich-based private investment firm focused on the health care industry, announced a growth investment and partnership with Ephicacy Consulting Group, Inc., ("Ephicacy"), a leading biometrics Contract Research Organization ("CRO") with operations in the United States, Canada, and India.
  • Ephicacy provides statistical programming, data management, and real-world evidence ("RWE") analytics services to pharmaceutical and biotechnology companies around the world.
  • "Ephicacy has been growing rapidly, and we are excited to partner with Ganesh and the rest of the team to accelerate growth."
  • Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 200 growing health care companies.

Great Point Partners Invests in JPA Health, Leading Marketing Communications Agency

Retrieved on: 
Wednesday, May 4, 2022

GREENWICH, Conn. and WASHINGTON, May 4, 2022 /PRNewswire-PRWeb/ -- Today Great Point Partners ("GPP"), a Greenwich-based private investment firm focused on the health care industry, announced the growth recapitalization of JPA Health ("JPA" or the "Company"). JPA is a high growth and leading public relations, marketing, and patient advocacy firm, providing strategic and creative services across the health care industry. The Company was founded in 2007 by Carrie Jones, its Chief Executive Officer. The Company is headquartered in Washington D.C., with offices in Boston, New York, and London, and has more than 90 employees.

Key Points: 
  • Great Point Partners a Greenwich-based private investment firm focused on the health care industry, announced the growth recapitalization of JPA Health.
  • GREENWICH, Conn. and WASHINGTON, May 4, 2022 /PRNewswire-PRWeb/ -- Today Great Point Partners ("GPP"), a Greenwich-based private investment firm focused on the health care industry, announced the growth recapitalization of JPA Health ("JPA" or the "Company").
  • JPA is a high growth and leading public relations, marketing, and patient advocacy firm, providing strategic and creative services across the health care industry.
  • Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 200 growing health care companies.

Humanigen Elects John Hohneker, MD, and Kevin Xie, PhD, to Board of Directors

Retrieved on: 
Wednesday, October 20, 2021

Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm, announced today that the Companys Board of Directors (the Board) has elected John Hohneker, MD, and Kevin Xie, PhD, to serve as independent directors of the Company, effective October 19, 2021.

Key Points: 
  • Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm, announced today that the Companys Board of Directors (the Board) has elected John Hohneker, MD, and Kevin Xie, PhD, to serve as independent directors of the Company, effective October 19, 2021.
  • As an executive he has advanced several programs from pre-clinical evaluation through Phase IV, including products in oncology and immunology.
  • He played a critical role in the development and commercialization of many blockbuster products including Cosentyx, Gleevec, Zometa, Tasigna, and Afinitor.
  • Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), is a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm.